On September 3, 2024 Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, reported that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York (Press release, Arbutus Biopharma, SEP 3, 2024, View Source [SID1234646312]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

-H.C. Wainwright 26th Annual Global Investment Conference: Formal Presentation on September 9, 2024 at 8:00 am ET
-Baird Global Healthcare Conference: Fireside Chat on September 10, 2024 at 8:30 am ET
To access the live webcast of the presentation and fireside chat please visit: View Source An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.